In the aggregate, our studies demonstrate potent activity of APG-2449 plus paclitaxel in preclinical models of ovarian cancer exhibiting FAK overexpression or amplification, including those insensitive to carboplatin. The gene discussed is PTK2; the disease is ovarian carcinoma.